A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-term remission from ulcerative colitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 26, 2010, Pages 12023-12027

  Vong, Linda ^a   Ferraz, Jose G P ^b   Panaccione, Remo ^b   Beck, Paul L ^b   Wallace, John L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Colon cancer; Eicosanoid; Inflammation; Inflammatory bowel disease

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON; COLON BIOPSY; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REMISSION; ULCERATIVE COLITIS; UPREGULATION;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; MIDDLE AGED; PROSTAGLANDIN D2; RECEPTORS, PROSTAGLANDIN; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

ANIMALIA; RODENTIA;

EID: 77955387223     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1004982107     Document Type: Article

References (29)

1. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434.
2. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V (1996) Changes in extent of ulcerative colitis: A study on the course and prognostic factors. Scand J Gastroenterol 31:260-266.
3. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2:612-619.
4. Serhan CN, et al. (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21:325-332.
5. Spite M, et al. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:1287-1291.
6. Murakami M, Kudo I (2006) Prostaglandin E synthase: A novel drug target for inflammation and cancer. Curr Pharm Des 12:943-954.
7. 2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 279:G238-G244.
8. Gilroy DW, et al. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701.
9. Rajakariar R, et al. (2007) Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 104:20979-20984.
10. Harris DW, Smith PR, Swan CH (1978) Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease. Gut 19:875-877.
11. Sharon P, Ligumsky M, Rachmilewitz D, Zor U (1978) Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 75:638-640.
12. McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD (1999) Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 13:1115-1117.
13. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL (1996) Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085.
14. Zamuner SR, Warrier N, Buret AG, MacNaughton WK, Wallace JL (2003) Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 52:1714-1720.
15. 2. Am J Pathol 167:1293-1300.
16. 4 receptor. Nat Med 8:1296-1302.
17. Arita M, et al. (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 102:7671-7676.
18. 4 analog treats hapteninduced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 101:15736-15741.
19. Vergnolle N, et al. (2004) Annexin 1 is secreted in situ during ulcerative colitis in humans. Inflamm Bowel Dis 10:584-592.
20. Martin GR, Perretti M, Flower RJ, Wallace JL (2008) Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 294:G764-G769.
21. Hammad H, et al. (2007) Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 204:357-367.
22. Fujitani Y, et al. (2002) Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 168:443-449.
23. Kim N, Luster AD (2007) Regulation of immune cells by eicosanoid receptors. Scientific World Journal 7:1307-1328.
24. 2) induces diverse biological responses via PPARgamma activation in cancer cells. Prostaglandins Other Lipid Mediat 62:23-32.
25. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A (1990) Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81:301-305.
26. Mahida YR, Wu K, Jewell DP (1989) Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 30:835-838. (Pubitemid 19167787)
27. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35:1593-1598.
28. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123:1598-1606.
29. Chávez-Piña AE, et al. (2008) Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol 155:857-864.